Peipei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peipei Zhang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Mingqiang Kang
Department of Thoracic Surgery, Fujian Medical University Union Hospital
4 shared publications Junlan Cai
The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China
3 shared publications- Mingqiang Kang
Department of Thoracic Surgery, Fujian Medical University Union Hospital
3 shared publications Weiguang Zhang
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China
3 shared publications- Jinlong Fang
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China
2 shared publications Ningzi Wu
The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China
2 shared publications
Latest Publications
- Open Access
A Pathological Image-Based Pathomics Signature Combined with Clinicopathological Features for Predicting Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma: A Development and External Validation Study
Background: Esophageal squamous cell carcinoma (ESCC) accounts for over 80% of esophageal cancer cases globally. Lymph node status is the strongest determinant of survival after resection, yet occult disease is found in about 17% of patients classified as node-negative. We developed a postoperative model estimating the probability of lymph node metastasis (LNM) from the resection specimen, combining nuclear features with clinicopathological variables. Methods: Of 477 consecutive ESCC patients undergoing radical esophagectomy without neoadjuvant therapy, 416 were analyzed (LNM 217, 52.2%). Nuclear features were extracted from H&E whole-slide images (20×) by QuPath optical-density detection; LASSO logistic regression selected 17. A nomogram combining the pathomics score with age, sex, tumor location, pT category and grade was validated by 10-fold cross-validation (out-of-fold, OOF) and applied without refitting to 101 patients from another institution. Results: OOF AUC was 0.821 (95% CI 0.779–0.858) for the combined model, versus 0.791 (clinical) and 0.762 (pathomics alone). The pathomics score remained an independent predictor (adjusted OR 2.47, 95% CI 1.80–3.39; p < 0.001). LNM prevalence rose across tertiles (15.8%, 55.1%, 85.6%; p < 0.001). Among 199 node-negative patients, high pathomics risk predicted worse 3-year overall survival (77.2% vs. 94.3%; p = 0.005) and progression-free survival (75.5% vs. 88.9%; p = 0.007). Externally (n = 101; LNM 24.8%), AUCs were 0.812, 0.801 and 0.697, and adding pathomics did not significantly improve discrimination. Conclusions: Within the development cohort, pathomics added modest but significant incremental value and identified node-negative patients at elevated risk. Because the model requires the resection specimen, it cannot guide preoperative treatment selection. External validation did not confirm incremental value: the clinical component; the pathomics signature did not.
Open AccessA Pathological Image-Based Pathomics Signature Combined with Clinicopathological Features for Predicting Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma: A Development and External Validation Study
Background: Esophageal squamous cell carcinoma (ESCC) accounts for over 80% of esophageal cancer cases globally. Lymph node status is the strongest determinant of survival after resection, yet occult disease is found in about 17% of patients classified as node-negative. We developed a postoperative model estimating the probability of lymph node metastasis (LNM) from the resection specimen, combining nuclear features with clinicopathological variables. Methods: Of 477 consecutive ESCC patients undergoing radical esophagectomy without neoadjuvant therapy, 416 were analyzed (LNM 217, 52.2%). Nuclear features were extracted from H&E whole-slide images (20×) by QuPath optical-density detection; LASSO logistic regression selected 17. A nomogram combining the pathomics score with age, sex, tumor location, pT category and grade was validated by 10-fold cross-validation (out-of-fold, OOF) and applied without refitting to 101 patients from another institution. Results: OOF AUC was 0.821 (95% CI 0.779–0.858) for the combined model, versus 0.791 (clinical) and 0.762 (pathomics alone). The pathomics score remained an independent predictor (adjusted OR 2.47, 95% CI 1.80–3.39; p < 0.001). LNM prevalence rose across tertiles (15.8%, 55.1%, 85.6%; p < 0.001). Among 199 node-negative patients, high pathomics risk predicted worse 3-year overall survival (77.2% vs. 94.3%; p = 0.005) and progression-free survival (75.5% vs. 88.9%; p = 0.007). Externally (n = 101; LNM 24.8%), AUCs were 0.812, 0.801 and 0.697, and adding pathomics did not significantly improve discrimination. Conclusions: Within the development cohort, pathomics added modest but significant incremental value and identified node-negative patients at elevated risk. Because the model requires the resection specimen, it cannot guide preoperative treatment selection. External validation did not confirm incremental value: the clinical component; the pathomics signature did not.
- Open Access
- 25 August 2026
- Published by MDPI AG in Preprints.org
A Pathological Image-Based Pathomics Signature Combined with Clinicopathological Features for Predicting Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma: A Development and External Validation Study
Background: Esophageal squamous cell carcinoma (ESCC) accounts for over 80% of esophageal cancer cases globally. Accurate preoperative prediction of lymph node metastasis (LNM) is critical for treatment decision-making, yet current clinical staging frequently underestimates nodal disease burden. Pathomics — the high-throughput quantitative analysis of histopathological images — offers an opportunity to capture tumor microenvironmental patterns invisible to routine microscopy. We aimed to develop and validate a pathomics-clinical integrated model for predicting LNM in resectable ESCC. Methods: A total of 477 consecutive ESCC patients who underwent radical esophagectomy were retrospectively enrolled. After excluding 61 patients with missing data, 416 patients were included in the final analysis (LNM-positive: 217, 52.2%). H&E-stained whole-slide images were acquired using a KFBIO KF-PRO-400-HI scanner at 20× magnification (pixel size 0.5 μm/px). Nuclear morphological features were extracted via QuPath hematoxylin optical density (OD)-based detection, yielding 17 pathomic features selected by LASSO-logistic regression. A combined clinical-pathomics nomogram was constructed and internally validated via 10-fold cross-validation (out-of-fold, OOF), with apparent (resubstitution) performance reported alongside to quantify optimism. Secondary analyses examined survival stratification within node-negative (pN0) patients and across whole-cohort risk groups. The final nomogram was additionally applied, without refitting, to an independent external cohort of 101 ESCC patients from a separate institution to assess transportability. Results: The combined nomogram achieved an out-of-fold (cross-validated) AUC of 0.821 (95% CI 0.779–0.858), compared with 0.791 for the clinical model and 0.762 for the pathomics-alone model. In multivariable analysis, the pathomics score remained an independent predictor of LNM (adjusted OR 2.47, 95% CI 1.80–3.39; P < 0.001), with significant incremental value over clinical variables alone (likelihood-ratio χ² = 35.5, P = 2.56e-09). Risk stratification by nomogram score tertiles showed a clear gradient of LNM prevalence: 15.8% (low-risk), 55.1% (intermediate-risk), and 85.6% (high-risk) (Cochran-Armitage trend P < 0.001). In the pN0 subgroup (n = 199), patients with high pathomics risk had significantly worse overall survival (3-year OS: 77.2% vs. 94.3%; log-rank P = 0.005) and progression-free survival (3-year PFS: 75.5% vs. 88.9%; log-rank P = 0.007). Externally, in an independent cohort of 101 patients from a separate institution (LNM+ = 25, 24.8%), the combined model achieved an AUC of 0.774 (95% CI 0.663–0.870), the clinical model 0.801, and the pathomics-alone model 0.685, confirming partial transportability of the clinical component while the pathomics signature showed limited generalizability across centers. Conclusions: The integration of quantitative pathomic features with conventional clinicopathological variables provides robust predictive power for LNM in ESCC and identifies a subset of node-negative patients at elevated risk of poor outcomes. These findings support the potential utility of pathomics as a complementary tool for preoperative risk stratification in ESCC. External validation in an independent cohort confirmed partial transportability of the clinical component but highlighted limited generalizability of the pathomics signature, underscoring the need for multi-center harmonization before clinical deployment.
- 25 August 2026
- Published by MDPI AG in Preprints.org
Open AccessA Pathological Image-Based Pathomics Signature Combined with Clinicopathological Features for Predicting Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma: A Development and External Validation Study
Background: Esophageal squamous cell carcinoma (ESCC) accounts for over 80% of esophageal cancer cases globally. Accurate preoperative prediction of lymph node metastasis (LNM) is critical for treatment decision-making, yet current clinical staging frequently underestimates nodal disease burden. Pathomics — the high-throughput quantitative analysis of histopathological images — offers an opportunity to capture tumor microenvironmental patterns invisible to routine microscopy. We aimed to develop and validate a pathomics-clinical integrated model for predicting LNM in resectable ESCC. Methods: A total of 477 consecutive ESCC patients who underwent radical esophagectomy were retrospectively enrolled. After excluding 61 patients with missing data, 416 patients were included in the final analysis (LNM-positive: 217, 52.2%). H&E-stained whole-slide images were acquired using a KFBIO KF-PRO-400-HI scanner at 20× magnification (pixel size 0.5 μm/px). Nuclear morphological features were extracted via QuPath hematoxylin optical density (OD)-based detection, yielding 17 pathomic features selected by LASSO-logistic regression. A combined clinical-pathomics nomogram was constructed and internally validated via 10-fold cross-validation (out-of-fold, OOF), with apparent (resubstitution) performance reported alongside to quantify optimism. Secondary analyses examined survival stratification within node-negative (pN0) patients and across whole-cohort risk groups. The final nomogram was additionally applied, without refitting, to an independent external cohort of 101 ESCC patients from a separate institution to assess transportability. Results: The combined nomogram achieved an out-of-fold (cross-validated) AUC of 0.821 (95% CI 0.779–0.858), compared with 0.791 for the clinical model and 0.762 for the pathomics-alone model. In multivariable analysis, the pathomics score remained an independent predictor of LNM (adjusted OR 2.47, 95% CI 1.80–3.39; P < 0.001), with significant incremental value over clinical variables alone (likelihood-ratio χ² = 35.5, P = 2.56e-09). Risk stratification by nomogram score tertiles showed a clear gradient of LNM prevalence: 15.8% (low-risk), 55.1% (intermediate-risk), and 85.6% (high-risk) (Cochran-Armitage trend P < 0.001). In the pN0 subgroup (n = 199), patients with high pathomics risk had significantly worse overall survival (3-year OS: 77.2% vs. 94.3%; log-rank P = 0.005) and progression-free survival (3-year PFS: 75.5% vs. 88.9%; log-rank P = 0.007). Externally, in an independent cohort of 101 patients from a separate institution (LNM+ = 25, 24.8%), the combined model achieved an AUC of 0.774 (95% CI 0.663–0.870), the clinical model 0.801, and the pathomics-alone model 0.685, confirming partial transportability of the clinical component while the pathomics signature showed limited generalizability across centers. Conclusions: The integration of quantitative pathomic features with conventional clinicopathological variables provides robust predictive power for LNM in ESCC and identifies a subset of node-negative patients at elevated risk of poor outcomes. These findings support the potential utility of pathomics as a complementary tool for preoperative risk stratification in ESCC. External validation in an independent cohort confirmed partial transportability of the clinical component but highlighted limited generalizability of the pathomics signature, underscoring the need for multi-center harmonization before clinical deployment.
- 24 April 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 156, 114677
Gut and Intratumoral microbiota: Key to lung Cancer development and immunotherapy
- 24 April 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 156, 114677
Gut and Intratumoral microbiota: Key to lung Cancer development and immunotherapy
- Open Access
- 27 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1457612
Biomarkers of lymph node metastasis in esophageal cancer
Esophageal cancer (EC) is among the most aggressive malignancies, ranking as the seventh most prevalent malignant tumor worldwide. Lymph node metastasis (LNM) indicates localized spread of cancer and often correlates with a poorer prognosis, emphasizing the necessity for neoadjuvant systemic therapy before surgery. However, accurate identification of LNM in EC presents challenges due to the lack of satisfactory diagnostic techniques. Imaging techniques, including ultrasound and computerized tomography scans, have low sensitivity and accuracy in assessing LNM. Additionally, the existing serological detection lacks precise biomarkers. The intricate and not fully understood molecular processes involved in LNM of EC contribute to current detective limitations. Recent research has shown potential in using various molecules, circulating tumor cells (CTCs), and changes in the microbiota to identify LNM in individuals with EC. Through summarizing potential biomarkers associated with LNM in EC and organizing the underlying mechanisms involved, this review aims to provide insights that facilitate biomarker development, enhance our understanding of the underlying mechanisms, and ultimately address the diagnostic challenges of LNM in clinical practice.
- 27 September 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1457612
Open AccessBiomarkers of lymph node metastasis in esophageal cancer
Esophageal cancer (EC) is among the most aggressive malignancies, ranking as the seventh most prevalent malignant tumor worldwide. Lymph node metastasis (LNM) indicates localized spread of cancer and often correlates with a poorer prognosis, emphasizing the necessity for neoadjuvant systemic therapy before surgery. However, accurate identification of LNM in EC presents challenges due to the lack of satisfactory diagnostic techniques. Imaging techniques, including ultrasound and computerized tomography scans, have low sensitivity and accuracy in assessing LNM. Additionally, the existing serological detection lacks precise biomarkers. The intricate and not fully understood molecular processes involved in LNM of EC contribute to current detective limitations. Recent research has shown potential in using various molecules, circulating tumor cells (CTCs), and changes in the microbiota to identify LNM in individuals with EC. Through summarizing potential biomarkers associated with LNM in EC and organizing the underlying mechanisms involved, this review aims to provide insights that facilitate biomarker development, enhance our understanding of the underlying mechanisms, and ultimately address the diagnostic challenges of LNM in clinical practice.
- 16 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt B) , 113096
SORBS2-Mediated inhibition of malignant behaviors in esophageal squamous cell carcinoma through TIMP3
- 16 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt B) , 113096
SORBS2-Mediated inhibition of malignant behaviors in esophageal squamous cell carcinoma through TIMP3
- Open Access
- 8 September 2023
- Published by Springer Nature in Cancer Cell International
- Vol. 23 (1) , 1-9
LncRNA SNHG1: role in tumorigenesis of multiple human cancers
Small nucleolar RNA host gene 1 (SNHG1) is an important member of the SNHG family. This family is composed of a group of host genes that can be processed into small nucleolar RNAs and play important biological functions. In an oncogenic role, the SNHG1 expression is increased in various cancers, which has immense application prospects in the diagnosis, treatment, and prognosis of malignant tumors. In this review, we have summarized the role and molecular mechanism of SNHG1 in the development of various cancers. In addition, we have emphasized the clinical significance of SNHG1 in cancers in our article. This molecule is expected to be a new marker for potential usage in the diagnosis, prognosis, and treatment of cancer.
- 8 September 2023
- Published by Springer Nature in Cancer Cell International
- Vol. 23 (1) , 1-9
Open AccessLncRNA SNHG1: role in tumorigenesis of multiple human cancers
Small nucleolar RNA host gene 1 (SNHG1) is an important member of the SNHG family. This family is composed of a group of host genes that can be processed into small nucleolar RNAs and play important biological functions. In an oncogenic role, the SNHG1 expression is increased in various cancers, which has immense application prospects in the diagnosis, treatment, and prognosis of malignant tumors. In this review, we have summarized the role and molecular mechanism of SNHG1 in the development of various cancers. In addition, we have emphasized the clinical significance of SNHG1 in cancers in our article. This molecule is expected to be a new marker for potential usage in the diagnosis, prognosis, and treatment of cancer.